Related Experiment Video

Updated: Apr 28, 2026

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry
04:32

A Uniform Shear Assay for Human Platelet and Cell Surface Receptors via Cone-plate Viscometry

Published on: June 5, 2019

7.1K

New advances in treating thrombotic diseases: GPVI as a platelet drug target

Peng Jiang1, Martine Jandrot-Perrus2

  • 1INSERM, UMR_S1148 LVTS, 46 rue Henri Huchard, Paris 75018, France; University Paris Diderot - Paris 7, UMR_S1148, 46 rue Henri Huchard, Paris 75018, France.

Drug Discovery Today
|June 17, 2014
PubMed

Insights

New antiplatelet drugs improve acute coronary syndrome treatment but have limitations. Inhibiting platelet glycoprotein VI (GPVI) offers a promising strategy for safer and more effective antithrombotic therapy.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) treatment has improved with novel antiplatelet drugs.
  • Despite advances, recurrent ischemic events and bleeding risks persist, particularly in stroke-prone patients.
  • Platelet glycoprotein VI (GPVI) inhibition is a potential therapeutic target for balancing antithrombotic efficacy and safety.

Purpose of the Study:

  • To review the physiological role of GPVI in hemostasis and thrombosis.
  • To evaluate the effectiveness and safety of GPVI inhibition strategies for antithrombotic therapy.

Main Methods:

  • Literature review of current knowledge on GPVI.
  • Analysis of evidence for GPVI-targeted antithrombotic strategies.

Main Results:

  • GPVI plays a crucial role in platelet activation and aggregation.
  • GPVI blockade demonstrates potential for high antithrombotic efficacy.
  • Early evidence suggests a favorable safety profile regarding bleeding risk.

Conclusions:

  • GPVI is a key mediator in thrombosis, making it an attractive target for novel antithrombotics.
  • Inhibiting GPVI may offer an improved risk-benefit profile compared to existing therapies for ACS and stroke prevention.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
611
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.9K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482